Member Info for Newuncle

Trills,

I know but at least this one was in the same month and quite interesting too

Hi Chesh,

One is mid 40s, other two are 24 and 32 so not a bad sample eh

Hi Trills, I think I have finally got it?

https://www.youtube.com/watch?v=i_Ngc8FBQVM&t=2376s

3 kits now for another one of the girls, they love the free offer.

Chesh,

DVRG SP reminds me of WBA FC, Boing Boing....down then right back up

131 kits given away so far so moving fast.

Just got 2 for the ladies

oops my bad

https://www.youtube.com/watch?v=a0-rBd2dh7w&list=PL7oYJS5OFsqhmRpSuD5sx4IX8kFnyEeDj

I am watching the recording on youtube

Hi Trills,

Can you tell me the title of the slide in question?

"Transportation of samples to the labs is one of the most costly parts in a large monitoring programme, in situ or on site sample analysis would be ideal!!!"

Hi guys,

All sounds positive, any chance of summarising the discussions please?

Nice one Chesh....do love a 100k buyer but will a 150k seller come next to spoil our fun?

You mean the same TP who forecast 94p here? I think I could just as good a job as those monkeys. And find better long holding investors for DVRG than TP have shown with their placings flippers for DVRG and MSYS that have been selling down all year. Sorry but I really don't believe anything they issue any more.

Fair enuf Trills. What do you think about incomes for 2022 then?

Re STC, the general feeling I got from the exchanges yesterday was that not many were impressed with STC recommending expensive skin treatment products because they would be unaffordable for many. But then how many people who wouldn't be able to afford the recommended products would have spent the money needed for the skin test anyway? I am thinking STC should know their target clientele and have focused on those who can afford the costs for the whole programme of skin tests + recommended products otherwise as people have said it could alienate those customers who could not afford the follow up products.

See Trills I'm not just a person who can only post about the share price after your little snipe yesterday. I called it right for this year's (2021) revenues when many were fantasising about much bigger numbers as nailed on here.

How about 2022 revenues then I wonder, perhaps if Q2 next year sees the significant ramp up of microtox PD production numbers, would £28m for full year 2022 be realistic, way too low or simply too high?

Quarter Revenue Quarter Revenue Growth Quarter Revenue Growth
Jan-Mar 2020 £500,000.00 Jan-Mar 2021 £1,300,000.00 160% Jan-Mar 2022 £1,950,000.00 50%
Apr-Jun 2020 £750,000.00 Apr-Jun 2021 £1,800,000.00 140% Apr-Jun 2022 £5,400,000.00 200%
Jly-Sep 2020 £1,250,000.00 Jly-Sep 2021 £3,000,000.00 140% Jly-Sep 2022 £9,000,000.00 200%
Oct-Dec 2020 £1,500,000.00 Oct-Dec 2021 £3,900,000.00 160% Oct-Dec 2022 £11,700,000.00 200%
Total 2020 £4,000,000.00 Total 2021 £10,000,000.00 150% Total 2022 £28,050,000.00 181%

Chesh I did say it would be a push to break £10m after 1st half numbers. At least now we can focus back on all things skin care related again now.

From GB posted on ADVFN yesterday:

gjbrandon24 Nov '21 - 19:12 - 9609 of 9622

@ragnarr is correct. AIM Rule 11 is very clear and requires a company to issue notice to the market if guidance is expected to be more than 10% above or below the figure already in the market.